TCBP Refutes A False Claim Made Earlier This Week On Social Media, Stating There Is Absolutely No Way The Company Is In Any Danger Of Being Delisted From The Nasdaq Stock Exchange
Portfolio Pulse from Benzinga Newsdesk
TC BioPharm (NASDAQ:TCBP) has refuted false social media claims about potential delisting from the Nasdaq. The company confirms it remains compliant with all listing requirements.
October 25, 2024 | 1:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TC BioPharm has addressed and refuted false claims about its potential delisting from Nasdaq, affirming its compliance with all listing requirements.
The refutation of false delisting claims by TC BioPharm is likely to reassure investors and stabilize or potentially increase the stock price in the short term. The company's confirmation of compliance with Nasdaq listing requirements is a positive signal.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100